GLP-1受体激动剂对2型糖尿病患者短期与长期代谢控制的影响(3)
第1页 |
参见附件。
[6] Yoder SM,Yang Q,Kindel TL,et al.Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats[J].Am J Physiol Gastrointest Lixer Physiol,2010,299(13):476-485.
[7] Gautier JF,Fetita S,Sobngwi E,et al.Biological actions of the incretins GIP and GLP-1and therapeutic perspectives in patients with type 2diabetes[J].Diabetes Matab,2005,31(3pt1):233.
[8] Gao Y,Yoon KH,Chuang LM,et al.Efficacy and safety of exenatide inpatients of Asian descent with type 2 diabetes inadequately controlled with metformin ormetformin and a sulphonylurea[J].Diabetes Res Clin Pract,2009,83(5):69-76.
[9] 施广德,张晓兰,黄文龙.艾塞那肽对2型糖尿病患者的疗效观察[J].中国糖尿病杂志,2011(10):770-772.
[10] 付鸿玉,刘冰梅,刘立波.艾塞那肽治疗2型糖尿病20例临床观察[J].中国医疗前沿,2011(18):32,45.
[11] Buse JB,Rosenstock J,Sesti G,et al.Liralutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomized,parallel-group,multinational,open-label trial(LEAD-6)[J].Lancet,2009,374(9683):39-47.
[12] Erdogdu O,Nathanson D,Sjoholm A,et al.Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-,PKA-and P13K/Akt-dependent pathways and requires GLP-1 receptor[J].Mol Cell Endocrionl.2010,325(1/2):26-35.
[13] Drucker DJ,Buse JB,Taylor K,et al.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized,open-label,non-inferiority study[J].Lancet,2008 372(9645):1240-250.
[14] 蔡玉立,文重远,黄兵.艾塞那肽治疗2型糖尿病对患者血脂影响的系统评价[J].医学研究杂志,2012,41(10):116-120.
(收稿日期:2014-03-03)
您现在查看是摘要介绍页,详见PDF附件。